Skin Cancer Diagnostics & Therapeutics
Skin Cancer Diagnostics & Therapeutics Market by Disease Type (Melanoma, Non-melanoma), Type (Diagnosis, Therapeutics) - Global Forecast 2024-2030
360iResearch Analyst
Want to know more about the skin cancer diagnostics & therapeutics market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[199 Pages Report] The Skin Cancer Diagnostics & Therapeutics Market size was estimated at USD 7.54 billion in 2023 and expected to reach USD 8.31 billion in 2024, at a CAGR 10.43% to reach USD 15.11 billion by 2030.

Skin Cancer Diagnostics & Therapeutics Market
To learn more about this report, request a free PDF copy

Skin cancer diagnostics involve a range of procedures and technologies designed to detect skin cancer at its earliest stages. The diagnostic process typically starts with a physical examination of the skin to identify suspicious lesions or moles. Once skin cancer is diagnosed, the therapeutic stage involves the treatment of the disease. Treatments can vary, as it depends on the type and stage of the cancer, and may include surgical procedures, including excision, Mohs surgery, and cryosurgery. Non-surgical options such as radiation therapy, chemotherapy, immunotherapy, and photodynamic therapy are also available and may be used either alone or in combination with surgical treatments. The rising incidence of skin cancer globally, increased healthcare investment and infrastructure, and growing awareness programs by governments and non-profit organizations have accentuated the need for skin cancer diagnostics and therapeutics. The introduction of personalized medicine and genomics into treatment protocols is also a potent driver. However, the high costs associated with advanced diagnostics and therapy, potential side effects and complications related to treatment, and disparities in access to healthcare services can impede the growth. Additionally, the procedural and technical difficulties associated with the diagnosis and therapy for skin cancer, coupled with a lack of skilled personnel, pose significant challenges. However, key players are exploring new areas of innovation, including the refinement of precision medicine techniques, the development of less toxic and more effective drug formulations, and exploring the potential of emerging fields such as immunotherapy and biologics to improve the efficiency and ease of skin care diagnostics and therapeutics.

Regional Insights

The Americas region, particularly the U.S. and Canada, harbors a sophisticated healthcare system with substantial investments in skin cancer research and diagnostics. Patient behavior is driven by high awareness levels and access to advanced therapies. Public and private entities show commitment through funding and initiatives to reduce the incidence and death rates associated with skin cancer. There is a high number of patents in the field, showcasing significant innovation in diagnostic tools such as mole mapping technologies, AI-driven image analysis, and therapeutic approaches, including targeted therapies and immunotherapies. The European Union shows substantial heterogeneity in the prevalence of skin cancer and healthcare access across member states. Investments in skin cancer research and healthcare infrastructures vary, but there is a concerted effort, showcased through initiatives such as the EU's Horizon 2020 program, to harmonize and advance the fight against skin cancer. In the APAC region, rising government support for improving the healthcare infrastructure and increasing insurance penetration is translating into a greater need for skin cancer care. Countries with advanced healthcare systems, such as Japan and Australia, lead in patient expenditure and adoption of innovative therapies.

Market Dynamics

The market dynamics represent an ever-changing landscape of the Skin Cancer Diagnostics & Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Growing Incidences and Rising Awareness of Skin Cancer Globally
    • Rising Government Initiatives for Early Detection and Skin Cancer Treatment
    • Proliferation in Research and Development Pipelines for Skin Cancer Diagnostics and Therapeutics
  • Market Restraints
    • High Cost Associated With the Various Skin Cancer Treatment
  • Market Opportunities
    • Advancements in Skin Cancer Diagnostics & Therapeutics
    • Developments of Skin Cancer Care in Emerging Nations
  • Market Challenges
    • Side Effects of Radiation Therapy for Skin Cancer
Market Segmentation Analysis
  • Disease Type: Growing need to ensure quick and early diagnosis and treatment of melanomas

    Melanoma is a severe form of skin cancer originating in the cells that produce melanin, the pigment that gives skin its color. For diagnostics, methods such as dermoscopy, skin biopsies, lymph node mapping, and imaging tests are in demand, while treatments range from surgical excision and chemotherapy to targeted therapy and immunotherapy. Preference for these options varies based on the tumor's characteristics, staging, and patient health. Compared to non-melanoma skin cancers, melanoma requires more aggressive treatment and ongoing surveillance due to its high metastatic potential. The prognosis generally worsens with later-stage diagnoses. Therefore, early and accurate diagnostics are heavily emphasized. Non-melanoma skin cancers predominantly include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), which are generally less aggressive than melanoma. Although these cancers are more common, they have a significantly lower risk of spreading, and the treatment often involves local procedures such as surgical excision, cryosurgery, or topical medications for early stages. Photodynamic therapy and radiation may also be utilized. Non-melanoma treatments and diagnostics are usually less expensive and less complex than those for melanoma.

  • Type: Advancements to improve therapeutics for skin cancer to cater to the rising incidences of skin cancer patients

    Diagnosis plays a highly critical role in the management of skin cancer, enabling early detection and thereby increasing the likelihood of successful treatment outcomes. The diagnostic segment includes various technologies and methods such as dermatoscopy, biopsy, imaging tests, and molecular diagnostics. While blood tests are not commonly used to diagnose skin cancer, they can provide valuable information about the patient's overall health and organ function, particularly in advanced cases where cancer may have spread. Dermatoscopy refers to a non-invasive diagnostic tool used to examine skin lesions. Imaging tests such as ultrasound, X-rays, computed tomography (CT) scans, positron emission tomography (PET), or magnetic resonance imaging (MRI) scans may be used to determine the spread of skin cancer to other parts of the body. When there is a suspicion of skin cancer spread, a lymph node biopsy can be performed to evaluate whether cancer cells have metastasized to the lymphatic system. A skin biopsy is the primary method used to diagnose skin cancer. It involves removing a sample of suspicious skin tissue, which is then examined under a microscope for the presence of cancer cells. The therapeutics for skin cancer range from surgical treatments to advanced systemic therapies and immunotherapies, with the choice of treatment usually dependent on the stage and type of skin cancer. Chemotherapy remains a potent systemic treatment modality for various stages of skin cancer, particularly for metastatic or advanced disease. It involves the use of anti-cancer drugs that are administered orally or intravenously to destroy rapidly dividing cancer cells. Non-invasive therapies have gained traction as they offer significant advantages by targeting cancer cells while minimizing damage to surrounding healthy tissue. These therapies include topical treatments, radiotherapy, or photodynamic therapy. Surgical procedures range from minimally invasive techniques such as cryosurgery, which involves freezing and destroying abnormal tissue, to more extensive surgeries such as Mohs surgery, which removes cancerous tissue layer by layer while preserving as much healthy tissue as possible.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Skin Cancer Diagnostics & Therapeutics Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Skin Cancer Diagnostics & Therapeutics Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Skin Cancer Diagnostics & Therapeutics Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Skin Cancer Diagnostics & Therapeutics Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Skin Cancer Diagnostics & Therapeutics Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Skin Cancer Diagnostics & Therapeutics Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Skin Cancer Diagnostics & Therapeutics Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Skin Cancer Diagnostics & Therapeutics Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Skin Cancer Diagnostics & Therapeutics Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Skin Cancer Diagnostics & Therapeutics Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Skin Cancer Diagnostics & Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Skin Cancer Diagnostics & Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • FDA Approves First AI-Powered Skin Cancer Diagnostic Tool

    The U.S. Food and Drug Administration has authorized the DermaSensor, an innovative artificial intelligence-driven device designed for the non-invasive diagnosis of skin cancer, encompassing melanoma, basal cell carcinoma, and squamous cell carcinoma. DermaSensor is a portable device employing spectroscopy to scrutinize skin lesions at both cellular and subcellular scales. It then applies a sophisticated, FDA-sanctioned algorithm to interpret the data. This tool was rigorously evaluated in the pivotal DERM-SUCCESS trial, which was spearheaded by researchers at the Mayo Clinic and involved over a thousand participants across twenty-two dedicated centers. [Published On: 2024-01-17]

  • Sun Pharma, Philogen Collaborate to Commercialise Skin Cancer Drug in Europe

    Sun Pharmaceutical Industries Ltd. announced a partnership with Philogen SpA, aimed at bringing the innovative oncological drug Nidlegy to market. This drug, which is undergoing Phase III clinical trials, represents a new biopharmaceutical approach to battling cancer. The licensing agreement covers the commercialization rights in key regions, notably Europe, Australia, and New Zealand. [Published On: 2023-05-30]

  • Incyte Announces FDA Approval Of Zynyz (Retifanlimab-Dlwr) For Treatment Of Metastatic/Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)

    Incyte Corporation announced that Zynyz (retifanlimab-dlwr), a novel humanized monoclonal antibody designed to inhibit the programmed death receptor-1 (PD-1), has received approval from the U.S. Food and Drug Administration (FDA) for use in adult patients battling metastatic or locally advanced recurrent Merkel Cell Carcinoma (MCC). This form of skin cancer, known for its rarity and aggressive behavior, typically manifests as a solitary, smooth, and often violet-hued skin growth, most common on areas of sun-exposed skin such as the head, neck, and extremities. [Published On: 2023-03-22]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Skin Cancer Diagnostics & Therapeutics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Skin Cancer Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AB Science, Abbott Laboratories, Agilent Technologies, Inc., Almirall, S.A., Amgen, Inc., AMLo Biosciences Ltd., AstraZeneca PLC, bioMérieux SA, Bristol-Myers Squibb Company, Castle Biosciences, Inc., Daiichi Sankyo Company, Limited, DAMAE Medical, DermTech, Inc. by Bausch Health Companies Inc., Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., NeraCare GmbH, Novartis AG, Pfizer Inc., QIAGEN N.V., Sanofi S.A., Sirnaomics, Inc., SkylineDx BV, Sun Pharmaceutical Industries Ltd., and Veriskin Inc..

Skin Cancer Diagnostics & Therapeutics Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the Skin Cancer Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Melanoma
    • Non-melanoma
  • Type
    • Diagnosis
      • Blood Tests
      • Dermatoscopy
      • Imaging Tests
      • Lymph Node Biopsy
      • Skin Biopsy
    • Therapeutics
      • Chemotherapy
      • Non-invasive Therapy
      • Surgery

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Skin Cancer Diagnostics & Therapeutics Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Skin Cancer Diagnostics & Therapeutics Market, by Disease Type
  7. Skin Cancer Diagnostics & Therapeutics Market, by Type
  8. Americas Skin Cancer Diagnostics & Therapeutics Market
  9. Asia-Pacific Skin Cancer Diagnostics & Therapeutics Market
  10. Europe, Middle East & Africa Skin Cancer Diagnostics & Therapeutics Market
  11. Competitive Landscape
  12. Competitive Portfolio
  13. List of Figures [Total: 20]
  14. List of Tables [Total: 376]
  15. List of Companies Mentioned [Total: 27]
Advancements in Skin Cancer Diagnostics & Therapeutics: A Healthy Future
December 29, 2023
Advancements in Skin Cancer Diagnostics & Therapeutics: A Healthy Future
Skin cancer is one of the most found types of cancer worldwide, with an incidence rate of approximately 2-3 million annually. Early detection is essential for effective treatment and management of skin cancer. With advancements in technology, skin cancer diagnostics and therapeutics have come a long way. From the initial diagnosis to treatment and beyond, medical professionals are armed with a wealth of resources to detect and manage skin cancer more effectively than ever before. This blog post explores the latest advancements in skin cancer diagnostics and therapeutics.

Early Detection:

Early detection is vital in the management of skin cancer, and there are several newer techniques that can help diagnose skin cancer at an early stage. One such technique is dermoscopy, which involves the use of a dermatoscope, a handheld device that can magnify and illuminate the skin, enabling a more thorough examination of suspicious areas. Artificial intelligence (AI) and machine learning (ML) are also being used to help diagnose skin cancer more efficiently. These technologies can analyze images of skin lesions, reducing the chances of misdiagnosis.

Treatment Options:

Treatment options for skin cancer depend on several factors like the type and stage of cancer, and the individual's age and overall health. While surgery is the most common form of treatment for skin cancer, there are several newer therapies and treatments available. These include topical immunotherapy, photodynamic therapy, and brachytherapy. Topical immunotherapy involves the application of a cream or lotion to the affected area, which enhances the immune response to attack the cancer cells. Photodynamic therapy is another newer treatment that uses light-sensitive drugs and a specific wavelength of light to destroy cancer cells. Brachytherapy involves the implantation of smallest radioactive seeds directly into the skin cancer lesion, delivering a targeted dose of radiation to the cancerous cells.

Personalized Treatment:

Personalized treatment involves tailoring skin cancer treatment based on a patient's unique genetic makeup. With advances in molecular biology, it is now possible to sequence the whole genome of a cancer cell. This information can help identify specific genetic mutations that are responsible for the development of certain types of skin cancer. With this knowledge, researchers can develop therapies that target specific genetic mutations, which can improve treatment outcomes.

Telemedicine and Remote Monitoring:

Telemedicine and remote monitoring are changing the way skin cancer care is delivered. With the increasing demand for remote consultations during the COVID-19 pandemic, telemedicine has come up as a viable option for patients. Remote monitoring can help detect new lesions and measure existing ones, allowing for more effective management of skin cancer from a distance.

Patient Education and Support:

Patient education and support are crucial in the management of skin cancer. Patients with skin cancer require regular monitoring and follow-up appointments, and educational resources can help them understand their diagnosis and manage their condition effectively. Online resources and support groups can provide patients with information and emotional support, which can help improve treatment outcomes.

Advancements in skin cancer diagnostics and therapeutics offer hope for more effective management of skin cancer. Early detection, personalized treatment, and new therapies are changing the treatment landscape for skin cancer patients. As technology continues to advance, skin cancer patients will have more resources at their disposal to help manage their condition effectively. Patient education and support will continue to be a crucial component of skin cancer care, helping patients lead healthy and fulfilling lives.

Frequently Asked Questions
  1. How big is the Skin Cancer Diagnostics & Therapeutics Market?
    Ans. The Global Skin Cancer Diagnostics & Therapeutics Market size was estimated at USD 7.54 billion in 2023 and expected to reach USD 8.31 billion in 2024.
  2. What is the Skin Cancer Diagnostics & Therapeutics Market growth?
    Ans. The Global Skin Cancer Diagnostics & Therapeutics Market to grow USD 15.11 billion by 2030, at a CAGR of 10.43%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.